Sanders Capital LLC Acquires 26,367 Shares of Humana Inc. (NYSE:HUM)

Sanders Capital LLC raised its position in Humana Inc. (NYSE:HUM - Free Report) by 2.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,194,708 shares of the insurance provider's stock after purchasing an additional 26,367 shares during the quarter. Sanders Capital LLC owned 0.99% of Humana worth $303,109,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in HUM. FPC Investment Advisory Inc. acquired a new position in Humana during the 4th quarter worth about $27,000. Centricity Wealth Management LLC bought a new position in Humana during the 4th quarter worth approximately $30,000. LFA Lugano Financial Advisors SA boosted its stake in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. OFI Invest Asset Management acquired a new stake in shares of Humana during the fourth quarter worth $33,000. Finally, Atwood & Palmer Inc. raised its stake in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock worth $39,000 after buying an additional 60 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

Shares of HUM traded down $21.20 on Friday, reaching $264.41. 3,670,273 shares of the company's stock traded hands, compared to its average volume of 1,756,462. The stock's 50 day simple moving average is $265.75 and its two-hundred day simple moving average is $269.97. The stock has a market cap of $31.91 billion, a PE ratio of 26.57, a PEG ratio of 2.05 and a beta of 0.62. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.34%. Humana's dividend payout ratio (DPR) is 35.58%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HUM. Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research note on Wednesday, January 15th. Royal Bank of Canada reiterated an "outperform" rating and issued a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Truist Financial raised their target price on Humana from $290.00 to $325.00 and gave the company a "hold" rating in a research note on Friday, April 11th. Finally, Mizuho upped their price target on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Seventeen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $284.90.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.